psalexa
logo

Pertussis Therapeutics Pipeline Analysis

Pertussis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11264
Available Format:

Pertussis, also known as whooping cough, is a respiratory disease that is caused by bacterium Bordetella pertussis. Pertussis is most common in young children and infants. The infection occurs due to the attachment of bacteria to the cilia of the upper respiratory system. The bacteria releases toxins that damage cilia and causes airways to swell. The disease spread from person to person by sneezing or coughing. Pertussis can be symptomatized by runny nose, mild cough, low grade fever, and apnea. According to the data published by the Centers for Disease Control and Prevention, the number of people estimated to be infected with pertussis in 2015 are around 20,762, in the U.S. Emory University is in the process of developing Tdap for the treatment of pertussis. Boryung Pharmaceutical Co., Ltd. is in the process of developing DTaP-IPV combination vaccine for the treatment of pertussis. Some of the companies and universities having the pipeline of pertussis include Boryung Pharmaceutical Co., Ltd., Emory University, and others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry